Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 2394 2377

Website: www.biomx.com

Address:

22 Einstein Street, Floor 4, Ness Ziona, Israel

StockHolms Oct. 24 at 6:06 PM

$PHGE BiomX subsidiary Adaptive Phage Therapeutics 🤑 🦠 +💩 =💰💵 Check out Episode 2 of the series ‘Connected’ on Netflix. https://www.microbiometimes.com/biomx-announces-entry-into-merger-agreement-with-adaptive-phage-therapeutics-and-concurrent-50-million-financing/

0 · Reply

SaySomethingNice Oct. 22 at 10:32 AM

$PHGE My profit money will goes into here.. Glta.. - imo

0 · Reply

kamenrider888 Oct. 17 at 3:39 PM

$PHGE way over priced

1 · Reply

prismmarketview Oct. 17 at 2:50 PM

$PHGE BiomX Inc reported encouraging FDA feedback that could expand development pathways for its bacteriophage therapy BX004 in cystic fibrosis. The company said it has addressed all FDA queries related to its delivery device, with the Phase 2b trial on track for topline results in Q1 2026. https://prismmarketview.com/biomx-announces-fda-feedback-supporting-expanded-development-pathways-for-bx004-in-cystic-fibrosis/

0 · Reply

Rambu11 Oct. 17 at 2:09 PM

$PHGE thanks for the update after 2 months. To let us kno absolutely nothing . We all assumed that anyway no ?

0 · Reply

jctataio Oct. 17 at 1:05 PM

$PHGE 😀😀😀 https://ir.biomx.com/news-releases/news-release-details/biomx-provides-program-update-and-announces-new-fda-feedback $SPY $QQQ

0 · Reply

WallStWireAds Oct. 17 at 1:00 PM

$PHGE 🗞️ https://www.globenewswire.com/news-release/2025/10/17/3168600/0/en/BiomX-Provides-a-Program-Update-and-Announces-New-FDA-Feedback-Potentially-Expanding-BX004-Development-Pathways.html

0 · Reply

DrevanTheStillblade Oct. 17 at 7:55 AM

VRME is quietly loading a breakout. ✅ Golden cross near ✅ Cash flowing ✅ Treasury value hiding in plain sight This one could sneak into top gainers any day. $TRNR $SNTG $PHGE $BIOR

0 · Reply

kamenrider888 Oct. 16 at 3:04 PM

0 · Reply

jctataio Oct. 16 at 1:38 PM

$PHGE did anyone had chance watch investor webcast this am to share some insights? Please

0 · Reply

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 19, 2025, 8:19 AM EDT - 2 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 13, 2025, 11:48 AM EDT - 2 months ago

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 6:30 AM EDT - 2 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 2 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 3 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 3 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 5 months ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 4:57 PM EDT - 5 months ago

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 6:30 AM EDT - 5 months ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 6 months ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 1, 2025, 6:30 AM EDT - 7 months ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 6:30 AM EDT - 7 months ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 7 months ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 7 months ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 10:20 AM EST - 1 year ago

BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 12:03 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 1 year ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 1 year ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 1 year ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 10:25 AM EDT - 1 year ago

BiomX (PHGE) Q1 2024 Earnings Call Transcript

May 21, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 1 year ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 12:26 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript

Apr 3, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 1 year ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 1 year ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 1 year ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 4, 2024, 8:00 AM EST - 1 year ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Nov 30, 2023, 4:15 PM EST - 2 years ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023, 6:30 AM EST - 2 years ago

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Nov 23, 2023, 7:43 AM EST - 2 years ago

BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day

Nov 14, 2023, 6:30 AM EST - 2 years ago

BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 27, 2023, 8:00 AM EDT - 2 years ago

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

Oct 18, 2023, 8:00 AM EDT - 2 years ago

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

Oct 4, 2023, 6:34 AM EDT - 2 years ago

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

StockHolms Oct. 24 at 6:06 PM

0 · Reply

SaySomethingNice Oct. 22 at 10:32 AM

$PHGE My profit money will goes into here.. Glta.. - imo

0 · Reply

kamenrider888 Oct. 17 at 3:39 PM

$PHGE way over priced

1 · Reply

prismmarketview Oct. 17 at 2:50 PM

0 · Reply

Rambu11 Oct. 17 at 2:09 PM

$PHGE thanks for the update after 2 months. To let us kno absolutely nothing . We all assumed that anyway no ?

0 · Reply

jctataio Oct. 17 at 1:05 PM

$PHGE 😀😀😀 https://ir.biomx.com/news-releases/news-release-details/biomx-provides-program-update-and-announces-new-fda-feedback $SPY $QQQ

0 · Reply

WallStWireAds Oct. 17 at 1:00 PM

$PHGE 🗞️ https://www.globenewswire.com/news-release/2025/10/17/3168600/0/en/BiomX-Provides-a-Program-Update-and-Announces-New-FDA-Feedback-Potentially-Expanding-BX004-Development-Pathways.html

0 · Reply

DrevanTheStillblade Oct. 17 at 7:55 AM

VRME is quietly loading a breakout. ✅ Golden cross near ✅ Cash flowing ✅ Treasury value hiding in plain sight This one could sneak into top gainers any day. $TRNR $SNTG $PHGE $BIOR

0 · Reply

kamenrider888 Oct. 16 at 3:04 PM

0 · Reply

jctataio Oct. 16 at 1:38 PM

$PHGE did anyone had chance watch investor webcast this am to share some insights? Please

0 · Reply

TWITLIEDETECTOR Oct. 16 at 2:31 AM

$PHGE Not quite bullish yet

0 · Reply

kamenrider888 Oct. 15 at 4:03 PM

$PHGE Dont be fooled.. This stock is not worth more than 20-30cents.

1 · Reply

TrendingTheSwing Oct. 14 at 12:44 PM

$PHGE Amazing Pre-market, it climbs upward steadily

0 · Reply

TrendingTheSwing Oct. 13 at 7:56 PM

$ACET $PHGE 💥

0 · Reply

DarthGoat Oct. 9 at 6:43 PM

$PHGE OOOUUUUTT +11%

1 · Reply

Rambu11 Oct. 9 at 6:02 PM

$PHGE

0 · Reply

SaySomethingNice Oct. 9 at 5:33 PM

$PHGE Keep adding 👍 -

0 · Reply

John_DL Oct. 7 at 2:30 PM

$PHGE $GLTO $SPRB

0 · Reply

Rambu11 Oct. 7 at 1:36 PM

$PHGE

0 · Reply

VincentVanGoghh Oct. 7 at 2:12 AM

PRHI is flashing all the signals: oversold, golden cross brewing, micro float, and huge upside range. This is the kind of move that runs fast and surprises everyone. $4+ is just the first ceiling. $FORG $PHGE $REVB $LUNR $COST

0 · Reply

SPYmyQQQ Oct. 7 at 1:27 AM

🎯 Target Hit 🏁 📨 From Sep 10, 2025 💊 $PHGE 💵 Entry: $0.4796 ✅ Exit: $0.5517 💰 P/L: +15.03% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Rambu11 Oct. 1 at 9:29 PM

$PHGE something about to happen lets hope positive 🙏

1 · Reply

Market Cap	15.26M
Revenue (ttm)	0.00
Net Income (ttm)	-17.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	337,500
Avg Vol	386,508
Day's Range	N/A - N/A
Shares Out	26.56M
Stochastic %K	37%
Beta	1.45
Analysts	Sell
Price Target	$15.00